These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18784152)

  • 1. The 6-minute walk test in scleroderma--how measuring everything measures nothing.
    Impens AJ; Wangkaew S; Seibold JR
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v68-9. PubMed ID: 18784152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension.
    Gomberg-Maitland M; Huo D; Benza RL; McLaughlin VV; Tapson VF; Barst RJ
    J Heart Lung Transplant; 2007 Jul; 26(7):732-8. PubMed ID: 17613405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis.
    Schoindre Y; Meune C; Dinh-Xuan AT; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Jul; 36(7):1481-5. PubMed ID: 19487260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts?
    Pamidi S; Mehta S
    J Rheumatol; 2009 Feb; 36(2):216-8. PubMed ID: 19208554
    [No Abstract]   [Full Text] [Related]  

  • 6. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease.
    Wilsher M; Good N; Hopkins R; Young P; Milne D; Gibson A; Suppiah R; Ly J; Doughty R; Dalbeth N
    Respirology; 2012 May; 17(4):647-52. PubMed ID: 22256786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of six-minute walk test in systemic sclerosis.
    Rizzi M; Radovanovic D; Santus P; Airoldi A; Frassanito F; Vanni S; Cristiano A; Sarzi-Puttini P; Atzeni F
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):161-167. PubMed ID: 30277863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors relating to impaired stroke volume during the 6-minute walk test in patients with systemic sclerosis.
    Someya F; Mugii N; Oohata S
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):152-156. PubMed ID: 27463117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement.
    de Oliveira NC; dos Santos Sabbag LM; Ueno LM; de Souza RB; Borges CL; de Sá Pinto AL; Lima FR
    Scand J Rheumatol; 2007; 36(6):458-61. PubMed ID: 18092268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.
    Buch MH; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells AU; Matucci-Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM; Seibold JR
    Ann Rheum Dis; 2007 Feb; 66(2):169-73. PubMed ID: 16868020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension.
    Lammers AE; Diller GP; Odendaal D; Tailor S; Derrick G; Haworth SG
    Arch Dis Child; 2011 Feb; 96(2):141-7. PubMed ID: 20930016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients.
    Villalba WO; Sampaio-Barros PD; Pereira MC; Cerqueira EM; Leme CA; Marques-Neto JF; Paschoal IA
    Chest; 2007 Jan; 131(1):217-22. PubMed ID: 17218579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary function tests.
    Behr J; Furst DE
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v65-7. PubMed ID: 18784151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional evaluation of patients with chronic pulmonary hypertension.
    Guazzi M; Opasich C
    Ital Heart J; 2005 Oct; 6(10):789-94. PubMed ID: 16270468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring outcomes in PAH: the gap between the measures that are used and their validity.
    Furst DE
    Ann N Y Acad Sci; 2007 Jun; 1107():410-6. PubMed ID: 17804569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension.
    Peled N; Shitrit D; Fox BD; Shlomi D; Amital A; Bendayan D; Kramer MR
    J Rheumatol; 2009 May; 36(5):970-5. PubMed ID: 19369472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis.
    Kowal-Bielecka O; Delcroix M; Vonk-Noordegraaf A; Hoeper MM; Naeije R
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v39-41. PubMed ID: 18784140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the six-minute walk test predict peak oxygen uptake in men with heart transplant?
    Doutreleau S; Di Marco P; Talha S; Charloux A; Piquard F; Geny B
    Arch Phys Med Rehabil; 2009 Jan; 90(1):51-7. PubMed ID: 19154829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-minute walk test in obese children and adolescents: reproducibility and validity.
    Morinder G; Mattsson E; Sollander C; Marcus C; Larsson UE
    Physiother Res Int; 2009 Jun; 14(2):91-104. PubMed ID: 19003813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of the 6-minute walk test in obese adults.
    Beriault K; Carpentier AC; Gagnon C; Ménard J; Baillargeon JP; Ardilouze JL; Langlois MF
    Int J Sports Med; 2009 Oct; 30(10):725-7. PubMed ID: 19585400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.